Semaglutide 4mg Cartridge

Please note: This item is shipped directly from the manufacturer. Delivery may take slightly longer than usual, with an estimated turnaround time of 5 to 7 working days.

Novo-Lela Semaglutide 4mg Cartridge contains Semaglutide, a GLP-1 receptor agonist approved for the treatment of type 2 diabetes. Semaglutide mimics the activity of human glucagon-like peptide-1, enhancing glucose-dependent insulin secretion and suppressing glucagon secretion, which helps regulate blood sugar levels.

Semaglutide was developed as part of a new generation of incretin-based therapies, showing significant efficacy in lowering HbA1c levels and promoting weight loss. Clinical studies have demonstrated that Semaglutide produces substantial improvements in glycaemic control compared to placebo and even other GLP-1 receptor agonists, with notable benefits in weight management and cardiovascular outcomes.

Beyond its impact on glucose metabolism, Semaglutide also delays gastric emptying, contributing to improved postprandial glucose control and reduced appetite. Its mechanism of action makes it a powerful adjunct to lifestyle interventions in patients with type 2 diabetes and, increasingly, for those with obesity.

Benefits of Semaglutide:

• Blood Sugar Regulation: Semaglutide stimulates insulin secretion in response to elevated blood glucose levels and suppresses glucagon production, improving glycaemic control.
• Weight Loss Support: By reducing appetite and slowing gastric emptying, Semaglutide promotes sustained weight reduction.
• Cardiovascular Protection: Clinical evidence suggests that Semaglutide may reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes.

Dosage Instructions:

Novo-Lela Semaglutide is administered as a subcutaneous injection using a cartridge compatible with the appropriate syringes that are suuplied.

General guidelines are as follows:

• Type 2 Diabetes: Begin with 0.25 mg once weekly for the first four weeks. Increase to 0.5 mg once weekly, then up to 1.0 mg as needed for additional glycaemic control.
• Weight Management: In weight-management protocols, higher maintenance doses (up to 2.4 mg weekly) may be prescribed based on patient tolerance and treatment objectives.
• Administer injections on the same day each week, at any time of day, with or without meals.

Always follow your healthcare provider’s instructions, as dosing may vary depending on your individual response and treatment plan.

Side Effects:

While generally well tolerated, Semaglutide may cause some side effects:

• Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, or abdominal discomfort, especially during dose escalation, which often improves over time.
• Hypoglycemia: Low blood sugar is uncommon when used alone, but may occur if combined with other antidiabetic medications.
• Injection Site Reactions: Redness, itching, or mild pain at the injection site.
• Pancreatitis: Rare cases of pancreatic inflammation have been reported.
• Gallbladder Effects: There may be an increased risk of gallbladder-related events with long-term use.

Patients should discuss potential side effects and monitoring requirements with their healthcare provider before initiating therapy.

Half-life:

Semaglutide has a half-life of approximately one week, enabling convenient once-weekly dosing. Its extended duration of action contributes to stable blood glucose control and supports consistent weight management.

In summary, Novo-Lela Semaglutide 4mg Cartridge is an effective GLP-1 receptor agonist therapy for type 2 diabetes and weight management. It delivers clinically proven improvements in glycaemic control, supports weight loss, and may offer cardiovascular protection when used as part of a comprehensive treatment plan.